Literature DB >> 33231826

Correlation of exosomal microRNA clusters with bone metastasis in non-small cell lung cancer.

Xiao-Rong Yang1, Can Pi1, Ruoying Yu2, Xiao-Jun Fan2, Xiao-Xiao Peng1, Xu-Chao Zhang1, Zhi-Hong Chen1, Xue Wu2, Yang Shao3,4, Yi-Long Wu1, Qing Zhou5.   

Abstract

20-40% of lung cancer patients develop bone metastasis (BM) with significantly decreased overall survival. Currently, BM is mainly diagnosed by computerized tomography (CT) scan or magnetic resonance imaging (MRI) when symptom develops. Novel biomarkers with higher prediction value of BM are needed. Plasma-derived exosomal microRNAs had been isolated and sequenced of total 30 non-small cell lung cancer (NSCLC) patients including 16 with bone metastasis and 14 without bone metastasis. Hierarchical clustering based on the total miRNA profile can clearly separate cancer patients and healthy individuals (H), but not patients with (BM +) or without (BM-) BM. Weight Co-expression network of miRNAs (WGCNA) analyses identified three consensus clusters (A, B, C) of highly correlated miRNAs, among which cluster B (144 miRNAs) showed significantly differential expression in lung cancer patients, especially in BM + group. Pathway analysis of cluster B miRNAs revealed enrichment in metabolic pathways that may involve in preconditioning of the metastatic niche. Three differentially expressed miRNAs between BM + and BM- patients within cluster B were identified as miR-574-5p, a suppressor of Wnt/β-catenin pathway, was down-regulated, while miR-328-3p and miR-423-3p, two activators of the same pathway, were up-regulated in BM + patients. Cluster A miRNAs (n = 49) also showed trend of upregulation in BM + patients. Interestingly, pathway analysis indicated that 43 of them are associated with chromosome14, which has been suggested to promote epithelial-mesenchymal transition (EMT) and bone metastasis.

Entities:  

Keywords:  Bone metastasis; NSCLC; Plasma-derived exosomal microRNAs; WGCNA; Wnt/β-catenin pathway

Mesh:

Substances:

Year:  2020        PMID: 33231826      PMCID: PMC7882559          DOI: 10.1007/s10585-020-10062-y

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  43 in total

1.  The predictive value and potential mechanisms of miRNA-328 and miRNA-378 for brain metastases in operable and advanced non-small-cell lung cancer.

Authors:  Dianshui Sun; Xin Li; Maoqiang Ma; Jie Liu; Ying Xu; Lan Ye; Huaying Hou; Cuihong Wang; Xiaomei Li; Yuhua Jiang
Journal:  Jpn J Clin Oncol       Date:  2015-02-02       Impact factor: 3.019

2.  A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer.

Authors:  Po-Shun Wang; Cheng-Han Chou; Cheng-Han Lin; Yun-Chin Yao; Hui-Chuan Cheng; Hao-Yi Li; Yu-Chung Chuang; Chia-Ning Yang; Luo-Ping Ger; Yu-Chia Chen; Forn-Chia Lin; Tang-Long Shen; Michael Hsiao; Pei-Jung Lu
Journal:  Oncogene       Date:  2018-05-14       Impact factor: 9.867

3.  Risk factors for bone metastasis in completely resected non-small-cell lung cancer.

Authors:  Hui Wang; Yan Zhang; Hui Zhu; Jinming Yu
Journal:  Future Oncol       Date:  2016-11-21       Impact factor: 3.404

Review 4.  The diagnostic imaging of bone metastases.

Authors:  Walter Heindel; Raphael Gübitz; Volker Vieth; Matthias Weckesser; Otmar Schober; Michael Schäfers
Journal:  Dtsch Arztebl Int       Date:  2014-10-31       Impact factor: 5.594

5.  MiR-574-5p mediates the cell cycle and apoptosis in thyroid cancer cells via Wnt/β-catenin signaling by repressing the expression of Quaking proteins.

Authors:  Zhejia Zhang; Xinying Li; Qian Xiao; Zhiming Wang
Journal:  Oncol Lett       Date:  2018-02-15       Impact factor: 2.967

6.  MicroRNA gene expression deregulation in human breast cancer.

Authors:  Marilena V Iorio; Manuela Ferracin; Chang-Gong Liu; Angelo Veronese; Riccardo Spizzo; Silvia Sabbioni; Eros Magri; Massimo Pedriali; Muller Fabbri; Manuela Campiglio; Sylvie Ménard; Juan P Palazzo; Anne Rosenberg; Piero Musiani; Stefano Volinia; Italo Nenci; George A Calin; Patrizia Querzoli; Massimo Negrini; Carlo M Croce
Journal:  Cancer Res       Date:  2005-08-15       Impact factor: 12.701

7.  Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.

Authors:  Lee S Rosen; David Gordon; N Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; Maciej Krzakowski; Marek Pawlicki; Paul De Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John Seaman
Journal:  Cancer       Date:  2004-06-15       Impact factor: 6.860

Review 8.  Non-small-cell lung cancers: a heterogeneous set of diseases.

Authors:  Zhao Chen; Christine M Fillmore; Peter S Hammerman; Carla F Kim; Kwok-Kin Wong
Journal:  Nat Rev Cancer       Date:  2014-08       Impact factor: 60.716

9.  WGCNA: an R package for weighted correlation network analysis.

Authors:  Peter Langfelder; Steve Horvath
Journal:  BMC Bioinformatics       Date:  2008-12-29       Impact factor: 3.169

10.  Kinin and Purine Signaling Contributes to Neuroblastoma Metastasis.

Authors:  Henning Ulrich; Mariusz Z Ratajczak; Gabriela Schneider; Elena Adinolfi; Elisa Orioli; Enéas G Ferrazoli; Talita Glaser; Juliana Corrêa-Velloso; Poliana C M Martins; Fernanda Coutinho; Ana P J Santos; Micheli M Pillat; Ulrich Sack; Claudiana Lameu
Journal:  Front Pharmacol       Date:  2018-05-18       Impact factor: 5.810

View more
  6 in total

1.  Efficacy Evaluation of Zoledronic Acid Combined with Chemotherapy in the Treatment of Lung Cancer Spinal Metastases on Computed Tomography Images on Intelligent Algorithms.

Authors:  Wei Cao; Peng Zhang; Nana Dong; Anwen Hu; Jiwen Xiao; Dexin Zou; Shulin Xiang; Yanxia Qi
Journal:  Comput Math Methods Med       Date:  2022-05-06       Impact factor: 2.809

Review 2.  The role of exosomes in lung cancer metastasis and clinical applications: an updated review.

Authors:  Lei Yin; Xiaotian Liu; Xuejun Shao; Tao Feng; Jun Xu; Qi Wang; Shenghao Hua
Journal:  J Transl Med       Date:  2021-07-19       Impact factor: 5.531

Review 3.  The Emerging Role of MicroRNAs in Bone Diseases and Their Therapeutic Potential.

Authors:  Luis Alberto Bravo Vázquez; Mariana Yunuen Moreno Becerril; Erick Octavio Mora Hernández; Gabriela García de León Carmona; María Emilia Aguirre Padilla; Samik Chakraborty; Anindya Bandyopadhyay; Sujay Paul
Journal:  Molecules       Date:  2021-12-30       Impact factor: 4.411

4.  Using biological information to analyze potential miRNA-mRNA regulatory networks in the plasma of patients with non-small cell lung cancer.

Authors:  Wei Zhang; Qian Zhang; Li Che; Zhefan Xie; Xingdong Cai; Ling Gong; Zhu Li; Daishun Liu; Shengming Liu
Journal:  BMC Cancer       Date:  2022-03-21       Impact factor: 4.430

Review 5.  Classical epithelial-mesenchymal transition (EMT) and alternative cell death process-driven blebbishield metastatic-witch (BMW) pathways to cancer metastasis.

Authors:  Goodwin G Jinesh; Andrew S Brohl
Journal:  Signal Transduct Target Ther       Date:  2022-08-23

Review 6.  Liquid biopsies in primary and secondary bone cancers.

Authors:  Argia Ucci; Nadia Rucci; Marco Ponzetti
Journal:  Cancer Drug Resist       Date:  2022-06-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.